WHY WAS THIS FUNDED?

This award uses an Other Transaction (OT) authority, which is a special legal tool that allows federal agencies to enter into flexible agreements outside of traditional contracting rules, often to speed up research and development. HHS has used this authority extensively since the COVID-19 pandemic to rapidly develop vaccines, treatments, and other health security tools.

WHAT PUBLIC PROBLEM IS IT TRYING TO SOLVE?

The U.S. government needs a fast and flexible way to develop medical products like vaccines, drugs, and diagnostics that can protect Americans from pandemics, bioterrorism threats, and other public health emergencies. Traditional procurement processes can be too slow when urgent health threats arise.

WHO BENEFITS?

Pharmaceutical companies, biotechnology firms, and research institutions that partner through ATI could receive funding to develop life-saving medical products. Ultimately, the American public benefits if new treatments or vaccines are successfully developed and made available during a health crisis.

WHAT ARE THE RISKS?

Because Other Transaction agreements are less regulated than standard government contracts, there is less built-in oversight, which can raise concerns about how taxpayer money is tracked and spent. A one billion dollar award managed through a nonprofit intermediary also requires strong auditing to ensure funds reach intended research goals efficiently.

WHAT HAPPENS IF FUNDING IS REMOVED?

If this contract were cancelled, the government's ability to quickly coordinate with private industry on developing medical countermeasures could slow down significantly. Research projects already underway through ATI's network could be delayed or stopped, potentially leaving gaps in the nation's health emergency preparedness.

ARGUMENTS FOR

• •Other Transaction authority allows faster, more flexible partnerships with cutting-edge biotech and pharmaceutical companies that might not work under rigid federal contracting rules, speeding up development of critical health tools.
• •Investing in medical countermeasure development now can help the U.S. respond more quickly and effectively to future pandemics or biological threats, potentially saving many lives.
• •ATI has an established track record managing large government research consortia, suggesting institutional experience that can reduce waste and keep projects organized.

ARGUMENTS AGAINST

• •The reduced oversight built into Other Transaction agreements compared to standard contracts makes it harder for Congress and the public to verify that one billion dollars is being spent responsibly.
• •The contract runs through 2030, locking in a very large sum for years, which limits flexibility if national health priorities shift or if early results show poor performance.
• •Routing funds through a nonprofit intermediary adds an administrative layer between taxpayer dollars and the actual research being done, which critics argue can reduce transparency and accountability.